Nkarta, Inc. (NASDAQ:NKTX) Director Simeon George Acquires 2,000,000 Shares

Nkarta, Inc. (NASDAQ:NKTX) Director Simeon George purchased 2,000,000 shares of Nkarta stock in a transaction that occurred on Wednesday, March 27th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $20,000,000.00. Following the acquisition, the director now owns 1,548,341 shares in the company, valued at $15,483,410. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Nkarta Stock Down 2.5 %

Shares of NKTX opened at $10.81 on Friday. The business’s 50 day simple moving average is $10.91 and its 200-day simple moving average is $5.94. Nkarta, Inc. has a 1 year low of $1.28 and a 1 year high of $16.24.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.05. Research analysts predict that Nkarta, Inc. will post -2.34 EPS for the current fiscal year.

Institutional Trading of Nkarta

Institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. raised its stake in shares of Nkarta by 18.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,749,101 shares of the company’s stock valued at $28,448,000 after acquiring an additional 745,757 shares during the period. Wasatch Advisors LP grew its stake in shares of Nkarta by 43.1% during the first quarter. Wasatch Advisors LP now owns 3,913,676 shares of the company’s stock valued at $13,894,000 after buying an additional 1,179,466 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Nkarta by 64.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,879,662 shares of the company’s stock worth $47,797,000 after buying an additional 1,520,473 shares during the period. BlackRock Inc. raised its holdings in shares of Nkarta by 0.8% in the first quarter. BlackRock Inc. now owns 3,221,996 shares of the company’s stock worth $11,438,000 after buying an additional 25,628 shares during the period. Finally, Commodore Capital LP bought a new stake in shares of Nkarta during the 4th quarter worth approximately $18,018,000. 80.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Mizuho decreased their price objective on Nkarta from $31.00 to $25.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Canaccord Genuity Group increased their target price on Nkarta from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday. Raymond James reissued an “outperform” rating and issued a $16.00 price objective (up previously from $13.00) on shares of Nkarta in a report on Friday, March 22nd. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Nkarta in a research note on Friday, March 22nd. Finally, HC Wainwright cut their price target on Nkarta from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Nkarta has an average rating of “Buy” and an average target price of $17.83.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.